One of Scher’s weaker arguments is that approving Provenge could cause other trials in HRPC to use Provenge in the control arm. This is a weak argument because, if it turns out that Provenge is no better than a placebo, the trials in question will effectively be placebo-controlled.
Essentially all of Scher's arguments are pretty poor. The only exception is the one you pointed out about inconsistency within the FDA - and that isn't likely to win friends or influence people in CBER.
Market Data 
Markets 
AI
